FDA issues Class I recall on insulin syringes due to risk of death

The U.S. Food and Drug Administration (FDA) is spreading the word about recalled lots of insulin syringes manufactured by Cardinal Health. A line of Monoject U-100 1 mL insulin syringes has an apparent manufacturing defect that leaves them incompatible with needleless IV connectors. If used to administer insulin, there is a risk the patient will not receive the full dose, as fluids may fail to leave the syringe. 

Due to the risk posed by patients receiving an inadequate dose of insulin—including hypoglycemia and death—the FDA has given this recall a Class I designation, reserved for the most serious cases. There have been no reported injuries or deaths.

Cardinal Health alerted known customers directly  about the recall in a letter sent on Sept. 25. However it is possible not all of the syringes were removed from supplies and clinical settings. Details on the recall are below.

What is being recalled?

Images of the recalled syringes

The product in questions is Monoject U-100 mL Insulin Syringe Luer Lock with Tip Cap Soft Pack—specifically those with the extended conical tip. The associated code is 1199100777 and the following lots are affected:

Lot Numbers: 

  • 221201
  • 230201
  • 230202

Unique Device Identifier (UDI): 

  • (01)10192253034783 (EA)
  • (01)20192253034780 (BX)
  • (01)50192253034781 (CS)

If any patient or clinician has a syringe with any of these lot or UDI numbers, they must not be used to push insulin through any IV connector. 

Next Steps

Cardinal Health is asking for an inventory check from anyone who may be in possession of the recalled syringes. They should not be used. Instead, seek a replacement by contacting the company at GMB-FieldCorrectiveAction@cardinalhealth.com 

The FDA and Cardinal Health ask that this alert be shared to spread awareness. The full recall notice can be found here.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos. 

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.